Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, NY 13501, USA.
J Am Coll Cardiol. 2010 Oct 5;56(15):1216-24. doi: 10.1016/j.jacc.2010.08.600.
The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibrillation (AF).
Safe and effective pharmacological management of AF remains one of the greatest unmet medical needs.
The electrophysiological effects of dronedarone (10 μmol/l) and a relatively low concentration of ranolazine (5 μmol/l) separately and in combination were evaluated in canine isolated coronary-perfused right and left atrial and left ventricular preparations as well as in pulmonary vein preparations.
Ranolazine caused moderate atrial-selective prolongation of action potential duration and atrial-selective depression of sodium channel-mediated parameters, including maximal rate of rise of the action potential upstroke, leading to the development of atrial-specific post-repolarization refractoriness. Dronedarone caused little or no change in electrophysiological parameters in both atrial and ventricular preparations. The combination of dronedarone and ranolazine caused little change in action potential duration in either chamber but induced potent use-dependent atrial-selective depression of the sodium channel-mediated parameters (maximal rate of rise of the action potential upstroke, diastolic threshold of excitation, and the shortest cycle length permitting a 1:1 response) and considerable post-repolarization refractoriness. Separately, dronedarone or a low concentration of ranolazine prevented the induction of AF in 17% and 29% of preparations, respectively. In combination, the 2 drugs suppressed AF and triggered activity and prevented the induction of AF in 9 of 10 preparations (90%).
Low concentrations of ranolazine and dronedarone produce relatively weak electrophysiological effects and weak suppression of AF when used separately but when combined exert potent synergistic effects, resulting in atrial-selective depression of sodium channel-dependent parameters and effective suppression of AF.
本研究旨在评估决奈达隆与雷诺嗪联合应用对心房颤动(AF)的抑制作用。
安全有效的 AF 药物治疗仍是最大的未满足医学需求之一。
在犬离体冠状灌流右心房和左心房及左心室以及肺静脉标本中,分别评估及联合评估决奈达隆(10 μmol/L)和相对较低浓度雷诺嗪(5 μmol/L)的电生理效应。
雷诺嗪导致动作电位时程中度心房选择性延长,并导致钠通道介导的参数(包括动作电位上升最大速率)出现心房选择性抑制,从而引发心房后除极不应期。决奈达隆在心房和心室标本中对电生理参数几乎没有影响。决奈达隆和雷诺嗪联合应用对两腔室的动作电位时程几乎没有变化,但对钠通道介导的参数产生了强大的、有使用依赖性的心房选择性抑制(动作电位上升最大速率、兴奋的舒张阈值以及允许 1:1 反应的最短周期长度),并显著延长后除极不应期。单独使用时,决奈达隆或低浓度雷诺嗪分别使 17%和 29%的标本中 AF 不易诱导。联合使用时,这两种药物可抑制 9/10(90%)标本中的 AF 及触发活动,从而防止 AF 的诱导。
低浓度雷诺嗪和决奈达隆单独使用时产生相对较弱的电生理效应和较弱的 AF 抑制作用,但联合应用时可发挥协同作用,导致钠通道依赖性参数的心房选择性抑制,并有效抑制 AF。